Project Grant P01CA278735
- This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides $456,103 in funding to The Feinstein Institutes for Medical Research to develop integrated risk models for endometrial cancer. The project aims to enhance early detection of endometrial cancer by determining the burden of rare genetic risk factors and creating predictive models that integrate genetic and non-genetic factors such as BMI, diabetes, and PCOS. The research will...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,768 to the University of New Mexico to conduct research focused on understanding the fundamental biological mechanisms of human papillomavirus (HPV)-induced tumors and precancerous lesions. The award aims to elucidate how inhibition of the MEK/ERK signaling pathway can lead to regression of HPV-driven tumors, with the goal of advancing scientific knowledge that can enable improved...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $132,825 to the Sloan-Kettering Institute for Cancer Research to develop and validate prognostic models for Black women with endometrial cancer following hysterectomy. The key products and services to be delivered include: Building a robust prognostic tool tailored for Black endometrial cancer patients to predict 3- and 5-year post-hysterectomy survival using clinical and epidemiological...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $3,277,279 to Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) to develop and evaluate English and Spanish smartphone Embodied Conversational Agents (ECAs) to improve follow-up rates for patients with abnormal cervical cancer screening results. The ECAs will provide follow-up recommendations, motivational interviewing, and facilitate communication...
- This Project Grant, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), provides $627,148.00 to the University of Maryland, College Park to develop an injectable, low-cost ablative therapy based on ethyl cellulose-ethanol gel for treating cervical dysplasia. The goal is to create an alternative to current costly and technically complex cervical cancer prevention solutions that are not practical for use in medically underserved regions. The project...
- This federal Cooperative Agreement award from the National Cancer Institute (CFDA 93.397 - Cancer Centers Support Grants) provides $2,255,110.00 to the University of North Carolina at Chapel Hill to establish the Cancer Health Disparities SPORE in Endometrial Cancer. The primary objective of this 5-year project is to investigate the biological and social factors driving health disparities in endometrial cancer, which is increasing in frequency and mortality. The research team will leverage three...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $551,975 to The University of Texas Southwestern Medical Center (UT Southwestern) to investigate the mechanisms and consequences of PAX2 inactivation in the initiation of endometrial carcinogenesis. The research aims to understand how PAX2 gene silencing triggers endometrial cancer development, as well as the functional role of PAX2 as a tumor suppressor in endometrial...
- This $1,529,953 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research at the University of Miami to understand the genomic landscape of endometrial cancer in Black women. The project aims to advance scientific understanding of this disease and its impact on a population that is disproportionately affected. The research will be conducted by the University of Miami's Office of Research Administration -...
- This federal Project Grant award of $1,394,304.00, awarded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research Program (CFDA 93.865), supports research to understand the relationship between obesity, endometrial hyperplasia, and endometrial cancer risk in women. The project, titled "Understanding Endometrial Tissue Field Defects in Obesity-Related Endometrial Hyperplasia", is a...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $371,161 to develop advanced AI-based risk models for cervical cancer screening in low-resource settings. The project aims to leverage time-series imaging data and self-supervised learning to enhance the diagnostic accuracy of automated visual evaluation (AVE) models. The goal is to create a comprehensive risk stratification system that combines imaging data, HPV...
This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) for $2,801,881 aims to improve clinical management and outcomes for patients with endometrial cancer (EC) and pre-cancerous atypical endometrial hyperplasia (AEH). The University of New Mexico Health Sciences Center, the awardee, will work to: 1) prevent the transition of AEH to EC, 2) prevent the progression of EC after initial treatment, and 3) prevent treatment-associated breast cancer. The project will systematically evaluate different progestin compounds to identify the most effective option for EC-AEH prevention and treatment, while also addressing concerns around increased breast cancer risk. This 5-year award, running from August 2025 to July 2030, supports a collaborative research effort to develop safer and more effective strategies for managing EC and AEH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.8m | 8/7/25 |